Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report
European Thyroid Journal · 01.02.2023 · 12 (1)
DOI: 10.1530/etj-22-0179 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Thyroid Journal, erschienen am 01.02.2023. Verfasst von Inês Damásio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated. Recently, several patient-tailored therapies for ATC are emerging due to advances in molecular profiling of these tumors. Entrectinib is a potent oral selective inhibitor of neutrotrophic tropomyosin receptor kinase ( NTRK ), ROS1 , and anaplastic lymphoma kinase fusions. The experience regarding ATC and other thyroid carcinomas, particularly in the neoadjuvant setting, is minimal. Case report We present a case of a 51-year-old female patient presenting with a bulky mass of the left thyroid lobe measuring 100 × 108 × 80 mm that was considered surgically unresectable. While waiting for next-generation sequence (NGS) profiling, lenvatinib was initiated. There was an initial clinical and imagiologic response; however, progression occurred after 12 weeks, and at this time NGS identified an ETV6-NTRK3 fusion and entrectinib was started. After 12 weeks, tumor diameters reduced to a minimum of 68×60×49 mm, and the patient underwent total thyroidectomy plus central lymphadenectomy. Histological diagnosis confirmed an ATC (pT4a R2 N1a). Adjuvant radiotherapy (RT) (60 Grays) with weekly paclitaxel (45 mg/m 2 ) was then administered followed by maintenance entrectinib 600 mg daily. Fluorodeoxyglucose positron emission tomography performed 3 months after completion of RT showed only non-specific uptake in the posterior wall of the hypopharynx and larynx, suggestive of inflammation.
Conclusion
We report the first case of an ATC with a dramatic response to neoadjuvant therapy with entrectinib, which enabled surgical resection of an ab initio unresectable tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
- Nova Medical School, Lisbon, Portugal.
- Radiology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon Portugal.
- Molecular Pathobiology Research Unit (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
- Pathology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
- Head and Neck Surgery Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
ORCID-Profile: Inês Damásio, Joana Simões-Pereira
Zitieren
APA
Damásio, I., Simões-Pereira, J., Donato, S., Horta, M., Cavaco, B. M., Rito, M., Gomes, P., & Leite, V. (2023). Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. European Thyroid Journal, 12(1). https://doi.org/10.1530/etj-22-0179
Vancouver
Damásio I, Simões-Pereira J, Donato S, Horta M, Cavaco BM, Rito M, et al. Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. European Thyroid Journal. 2023;12(1). doi:10.1530/etj-22-0179
BibTeX
@article{Damsio2023,
author = {Damásio, Inês and Simões-Pereira, Joana and Donato, Sara and Horta, Mariana and Cavaco, Branca Maria and Rito, Miguel and Gomes, Pedro and Leite, Valeriano},
title = {Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report},
journal = {European Thyroid Journal},
year = {2023},
volume = {12},
number = {1},
doi = {10.1530/etj-22-0179}
}
EUVIMED